Repositioning approved antitumor drugs for different cancers is a cost-effective approach. Gilteritinib was FDA-approved for the treatment of FLT3-mutated acute myeloid leukemia in 2018. However, the ...
In cancer treatment, metabolic reprogramming has emerged as a focal point of research, with cholesterol metabolism receiving widespread attention due to its critical role in tumor. Cholesterol, as an ...
Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever ...
Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
A total of 84% of patients who received the 30 mg dose were able to meet AHA-recommended LDL-C levels. (yalcinsonat1/iStock/Getty Images Plus) The highest dose of ...
This depletion process ultimately relies on an enzyme called cathepsin A (CTSA). The researchers found that blocking CTSA ...
Share on Pinterest A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A new study investigates the cholesterol-lowering effects of an ...
Some types of cancer have a relentless appetite for the metabolite cholesterol, using as much as they can access to accelerate their growth beyond the capabilities of normal cells. Research by ...
The Hearty Soul on MSN
Surprising Effects Cholesterol Drugs Have on the Whole Body
Cholesterol drugs side effects go beyond cholesterol. New research links statins to brain changes, weight gain, and lower ...
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A once-daily oral PCSK9 inhibitor reduced LDL in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results